IntelliPharmaCeutics Intl Company Profile (NASDAQ:IPCI)

About IntelliPharmaCeutics Intl (NASDAQ:IPCI)

IntelliPharmaCeutics Intl logoIntellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. Based on this technology platform, it has developed various drug delivery systems and a pipeline of products, and product candidates in various stages of development, in therapeutic areas that include neurology and cardiovascular. Its pipeline of products includes Rexista Oxycodone, Regabatin XR, Generic Focalin XR, Generic Effexor XR, Generic Protonix, Generic Glucophage XR, Generic Seroquel XR, Generic Lamictal XR, Generic Keppra XR, Generic Pristiq and Generic Ranexa. Its generic product candidates also include Trazodone hydrochloride extended-release tablets and Carvedilol phosphate extended-release capsules.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $59.56 million
  • Outstanding Shares: 30,386,000
Average Prices:
  • 50 Day Moving Avg: $2.12
  • 200 Day Moving Avg: $2.53
  • 52 Week Range: $1.41 - $3.35
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 2.11
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $2.92 million
  • Price / Sales: 20.40
  • Book Value: $0.03 per share
  • Price / Book: 65.33
Profitability:
  • EBIDTA: ($9,220,000.00)
  • Net Margins: -451.40%
  • Return on Assets: -234.43%
Debt:
  • Current Ratio: 0.94%
  • Quick Ratio: 0.94%
Misc:
  • Average Volume: 335,887 shs.
  • Beta: 0.92
  • Short Ratio: 6.9
 

Frequently Asked Questions for IntelliPharmaCeutics Intl (NASDAQ:IPCI)

What is IntelliPharmaCeutics Intl's stock symbol?

IntelliPharmaCeutics Intl trades on the NASDAQ under the ticker symbol "IPCI."

How were IntelliPharmaCeutics Intl's earnings last quarter?

IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) released its earnings results on Thursday, October, 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.07). The company earned $0.56 million during the quarter, compared to analyst estimates of $0.50 million. View IntelliPharmaCeutics Intl's Earnings History.

Where is IntelliPharmaCeutics Intl's stock going? Where will IntelliPharmaCeutics Intl's stock price be in 2017?

3 equities research analysts have issued 12 month price targets for IntelliPharmaCeutics Intl's stock. Their predictions range from $2.00 to $8.00. On average, they expect IntelliPharmaCeutics Intl's stock price to reach $5.33 in the next year. View Analyst Ratings for IntelliPharmaCeutics Intl.

What are analysts saying about IntelliPharmaCeutics Intl stock?

Here are some recent quotes from research analysts about IntelliPharmaCeutics Intl stock:

  • 1. Aegis analysts commented, "We believe the stay is more likely to last longer than 30 months, as is typical in most patent dispute cases." (4/18/2017)
  • 2. According to Zacks Investment Research, "Intellipharmaceutics International Inc. is engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Its products include Effexor XR and Protonix. The Company offers products in different stages of development in therapeutic areas, including neurology, cardiovascular, and GIT. Intellipharmaceutics International Inc. was formerly known as IntelliPharmaCeutics Ltd. and is based in Toronto, Canada. " (4/17/2017)

Are investors shorting IntelliPharmaCeutics Intl?

IntelliPharmaCeutics Intl saw a drop in short interest in April. As of April 13th, there was short interest totalling 1,986,271 shares, a drop of 0.4% from the March 31st total of 1,993,772 shares. Based on an average daily volume of 170,409 shares, the short-interest ratio is currently 11.7 days.

Who are some of IntelliPharmaCeutics Intl's key competitors?

Who owns IntelliPharmaCeutics Intl stock?

IntelliPharmaCeutics Intl's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include First Foundation Advisors (0.90%) and Morgan Stanley (0.20%). View Institutional Ownership Trends for IntelliPharmaCeutics Intl.

Who sold IntelliPharmaCeutics Intl stock? Who is selling IntelliPharmaCeutics Intl stock?

IntelliPharmaCeutics Intl's stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley. View Insider Buying and Selling for IntelliPharmaCeutics Intl.

Who bought IntelliPharmaCeutics Intl stock? Who is buying IntelliPharmaCeutics Intl stock?

IntelliPharmaCeutics Intl's stock was acquired by a variety of institutional investors in the last quarter, including First Foundation Advisors. View Insider Buying and Selling for IntelliPharmaCeutics Intl.

How do I buy IntelliPharmaCeutics Intl stock?

Shares of IntelliPharmaCeutics Intl can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of IntelliPharmaCeutics Intl stock cost?

One share of IntelliPharmaCeutics Intl stock can currently be purchased for approximately $1.96.

Analyst Ratings

Consensus Ratings for IntelliPharmaCeutics Intl (NASDAQ:IPCI) (?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $5.33 (172.11% upside)

Analysts' Ratings History for IntelliPharmaCeutics Intl (NASDAQ:IPCI)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/11/2017Maxim GroupSet Price TargetBuy$6.00LowView Rating Details
4/18/2017AegisReiterated RatingHold$2.00LowView Rating Details
10/17/2016Brean CapitalSet Price TargetBuy$8.00N/AView Rating Details
10/13/2015MackieSet Price TargetBuy$12.00N/AView Rating Details
(Data available from 5/24/2015 forward)

Earnings

Earnings History for IntelliPharmaCeutics Intl (NASDAQ:IPCI)
Earnings by Quarter for IntelliPharmaCeutics Intl (NASDAQ:IPCI)
Earnings History by Quarter for IntelliPharmaCeutics Intl (NASDAQ:IPCI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/13/2016Q316($0.07)($0.07)$0.50 million$0.56 millionViewN/AView Earnings Details
7/13/2016Q216($0.09)($0.08)$0.80 million$0.56 millionViewN/AView Earnings Details
4/14/2016Q1($0.07)($0.09)$0.70 million$0.57 millionViewN/AView Earnings Details
10/9/2015Q315($0.05)($0.08)$1.30 million$0.84 millionViewN/AView Earnings Details
7/13/2015Q215($0.05)($0.06)$1.20 million$1.27 millionViewN/AView Earnings Details
4/14/2015Q1 2015($0.08)($0.04)$1.20 million$1.14 millionViewN/AView Earnings Details
2/23/2015Q4 2014($0.07)($0.06)$1.40 million$1.54 millionViewN/AView Earnings Details
10/15/2014Q3($0.05)($0.07)$2.40 million$1.07 millionViewN/AView Earnings Details
4/14/2014Q114$0.11$0.09$4.49 million$4.70 millionViewN/AView Earnings Details
2/18/2014($0.08)($0.31)ViewN/AView Earnings Details
4/3/2013Q113($0.12)($0.07)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for IntelliPharmaCeutics Intl (NASDAQ:IPCI)
Current Year EPS Consensus Estimate: $0.23 EPS
Next Year EPS Consensus Estimate: $0.93 EPS

Dividends

Dividend History for IntelliPharmaCeutics Intl (NASDAQ:IPCI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for IntelliPharmaCeutics Intl (NASDAQ:IPCI)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for IntelliPharmaCeutics Intl (NASDAQ:IPCI)
Latest Headlines for IntelliPharmaCeutics Intl (NASDAQ:IPCI)
Source:
DateHeadline
americanbankingnews.com logoIntelliPharmaCeutics Intl Inc (IPCI) PT Set at $6.00 by Maxim Group
www.americanbankingnews.com - May 13 at 6:26 PM
streetinsider.com logoIntellipharmaceutics (IPCI) Receives FDA Final Approval of Generic ... - StreetInsider.com
www.streetinsider.com - May 10 at 11:20 PM
streetinsider.com logoIntellipharmaceutics (IPCI) Receives FDA Final Approval of Generic Seroquel XR
www.streetinsider.com - May 10 at 6:19 PM
finance.yahoo.com logoIntellipharmaceutics Announces FDA Final Approval of Generic Seroquel XR®
finance.yahoo.com - May 10 at 6:19 PM
americanbankingnews.com logoShort Interest in IntelliPharmaCeutics Intl Inc (IPCI) Drops By 0.4%
www.americanbankingnews.com - May 5 at 1:22 PM
americanbankingnews.com logoIntelliPharmaCeutics Intl (IPCI) Getting Favorable Media Coverage, Study Shows
www.americanbankingnews.com - May 3 at 10:36 AM
americanbankingnews.com logoIntelliPharmaCeutics Intl (IPCI) Given News Impact Rating of 0.33
www.americanbankingnews.com - April 28 at 9:34 PM
americanbankingnews.com logoIntelliPharmaCeutics Intl (IPCI) Earns Daily Media Impact Score of 0.05
www.americanbankingnews.com - April 25 at 9:34 PM
americanbankingnews.com logoIntelliPharmaCeutics Intl (IPCI) Receives Media Sentiment Rating of 0.15
www.americanbankingnews.com - April 21 at 4:19 PM
finance.yahoo.com logoIntellipharmaceutics Reports Director Election Results
finance.yahoo.com - April 19 at 11:22 AM
americanbankingnews.com logoIntelliPharmaCeutics Intl Inc (IPCI) Given Buy Rating at Maxim Group
www.americanbankingnews.com - April 18 at 7:56 PM
americanbankingnews.com logoIntelliPharmaCeutics Intl (IPCI) Receiving Positive News Coverage, Study Finds
www.americanbankingnews.com - April 18 at 5:30 PM
americanbankingnews.com logoAegis Reaffirms Hold Rating for IntelliPharmaCeutics Intl Inc (IPCI)
www.americanbankingnews.com - April 18 at 10:37 AM
americanbankingnews.com logoIntelliPharmaCeutics Intl Inc (IPCI) Downgraded by Aegis to "Hold"
www.americanbankingnews.com - April 18 at 7:38 AM
americanbankingnews.com logoMaxim Group Reaffirms "Buy" Rating for IntelliPharmaCeutics Intl Inc (IPCI)
www.americanbankingnews.com - April 18 at 7:38 AM
americanbankingnews.com logoIntelliPharmaCeutics Intl Inc (IPCI) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 17 at 11:47 PM
finance.yahoo.com logoIntellipharmaceutics International, Inc. :IPCI-US: Earnings Analysis: Q1, 2017 By the Numbers : April 14, 2017
finance.yahoo.com - April 14 at 5:54 PM
americanbankingnews.com logoIntelliPharmaCeutics Intl (IPCI) Receiving Positive News Coverage, Report Shows
www.americanbankingnews.com - April 14 at 12:48 PM
americanbankingnews.com logoIntelliPharmaCeutics Intl Inc (IPCI) Downgraded by Aegis to Hold
www.americanbankingnews.com - April 14 at 11:00 AM
americanbankingnews.com logoIntelliPharmaCeutics Intl's (IPCI) Buy Rating Reiterated at Maxim Group
www.americanbankingnews.com - April 14 at 11:00 AM
finance.yahoo.com logoIntellipharmaceutics reports 1Q loss - Yahoo Finance - Yahoo Finance
finance.yahoo.com - April 12 at 9:04 AM
globenewswire.com logoIntellipharmaceutics Announces First Quarter 2017 Results - GlobeNewswire (press release)
globenewswire.com - April 12 at 9:04 AM
finance.yahoo.com logoIntellipharmaceutics Announces First Quarter 2017 Results
finance.yahoo.com - April 11 at 10:43 PM
americanbankingnews.com logoIntelliPharmaCeutics Intl Inc (IPCI) Lifted to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 25 at 8:29 AM
investopedia.com logoNektar Pharma Opioid Drug Shows Promise In Phase 3
www.investopedia.com - March 20 at 4:13 PM
seekingalpha.com logoIntelliPharmaCeutics International: Great Opportunity, But Not Right Now
seekingalpha.com - March 17 at 6:09 PM
finance.yahoo.com logoINTELLIPHARMACEUTICS INTERNATIONAL INC. Financials
finance.yahoo.com - March 7 at 5:42 PM
seekingalpha.com logoFDA OKs Intellipharmaceutics' generic metformin; shares ahead 40% premarket - Seeking Alpha
seekingalpha.com - February 25 at 8:30 AM
nasdaq.com logoHealth Care Sector Update for 02/24/2017: IPCI,BMY,CEMP,MGLN ... - Nasdaq
www.nasdaq.com - February 25 at 8:30 AM
finance.yahoo.com logo8:03 am Intellipharmaceutics Intl receives FDA approval for its ANDA for metformin hydrochloride extended release tablets in the 500 mg and 750 mg strengths
finance.yahoo.com - February 24 at 7:15 PM
streetinsider.com logoIntellipharmaceutics (IPCI) Reports FDA Approval for 500 mg, 750 mg Generic Glucophage XR
www.streetinsider.com - February 24 at 10:14 AM
nasdaq.com logoETF Preview: ETFs, Futures Mixed Ahead of New Home Sales, Consumer Sentiment Data
www.nasdaq.com - February 24 at 10:14 AM
us.rd.yahoo.com logoIntellipharmaceutics Announces FDA Approval for 500 mg and 750 mg Generic Glucophage® XR
us.rd.yahoo.com - February 24 at 10:14 AM
globenewswire.com logoIntellipharmaceutics Announces 2016 Year End Results - GlobeNewswire (press release)
globenewswire.com - February 11 at 5:59 PM
investopedia.com logoFDA Accepts Intellipharmaceutics Painkiller (IPCI)
www.investopedia.com - February 3 at 6:30 PM
investopedia.com logoIntellipharmaceutics Painkiller Qualifies for FDA Review
www.investopedia.com - February 3 at 6:30 PM
streetinsider.com logoIntellipharmaceutics (IPCI) Reports FDA Acceptance for Filing of NDA for Rexista
www.streetinsider.com - February 3 at 4:42 AM
streetinsider.com logoIntellipharmaceutics (IPCI) Reports FDA Acceptance for Filing of NDA for Rexista - StreetInsider.com
www.streetinsider.com - February 2 at 11:41 PM
globenewswire.com logoIntellipharmaceutics Announces FDA Acceptance for Filing of NDA for Rexista™ (oxycodone hydrochloride extended release), an ...
globenewswire.com - February 2 at 6:38 PM
bizjournals.com logoResearch Reports Coverage on Healthcare Stocks -- Pacira Pharma, Supernus Pharma, Lipocine, and IntelliPharmaCeutics
www.bizjournals.com - January 12 at 6:27 PM
seekingalpha.com logoIntelliPharmaCeutics Intl (IPCI) Presents At 9th Annual Biotech Showcase 2017 Conference
seekingalpha.com - January 12 at 6:27 PM

Social

Chart

IntelliPharmaCeutics Intl (IPCI) Chart for Wednesday, May, 24, 2017

This page was last updated on 5/24/2017 by MarketBeat.com Staff